Rubius nets record $241M IPO as biotech investors show appetite for risk

The Massachusetts biotech sector's strength on the stock market has reached a new high, with cancer-fighting startup Rubius Therapeutics Inc. netting $241 million from a record-breaking IPO. Cambridge-based Rubius (Nasdaq: RUBY) is genetically engineering red blood cells to combat cancer and other diseases. The company originally said last month that it hoped to raise a maximum of $200 million, but ultimately sold roughly 10.5 million shares at $23 each late Tuesday. The $241 million sum surpasses…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news